Synthesis and Characterisation of Iron Oxide Nanoparticles Conjugated With Epidermal Growth Factor Receptor (Egfr) Monoclonal Antibody As Mri Contrast Agent for Cancer Detection Publisher Pubmed

Summary: Scientists report antibody-coated nanoparticles enhance MRI for tumor detection, promising earlier cancer diagnosis. #CancerResearch #MedicalImaging

Salehnia Z^{1, 2} ; Shahbazigahrouei D¹ ; Akbarzadeh A³ ; Baradaran B² ; Farajnia S⁴ ; Naghibi M⁵
Source: IET Nanobiotechnology Published:2019

Abstract

: The aim of this study is to synthesise superparamagnetic iron oxide nanoparticles conjugated with anti-epidermal growth factor receptor monoclonal antibody (ANTI-EGFR-SPION) and investigate its physicochemical characterisation and biocompatibility as a targeted magnetic resonance imaging (MRI) contrast agent for the EGFR-specific detection in EGFR expressing tumour cells. These particles employed biocompatible polymers, poly(D,L-lactide-co-glycolide) (PLGA) and polyethylene glycol aldehyde (PEG-aldehyde), to increase the half-life of particles in circulation and reduce their side effects. The Fe3O4-loaded PLGA-PEG-aldehyde nanoparticles were prepared by a modified water-in-oil-in-water double emulsion method. The EGFR antibody was conjugated to the surface of SPIONs using the aldehyde-amine reaction. Synthesised conjugates (nanoprobes) were characterised using Fourier transform infrared spectrophotometry, dynamic light scattering, transmission electron microscopy images, and vibrating-sample magnetometery, and the results showed that the conjugation was successful. The mean diameter of nanoprobes was about 25 nm. These nanoprobes exhibited excellent water-solubility, stability, and biocompatibility. Meanwhile, MR susceptibility test proved that synthesised nanoprobes can be managed for negative contrast enhancement. The results of this study suggested the potential use of these nanoprobes for non-invasive molecular MRI in EGFR detection in the future. © The Institution of Engineering and Technology 2019